HK Stock Market Move | CSPC PHARMA (01093) rose more than 3% at the end of the day. The second application for the market approval of Simuglucagon Injection was accepted.

CSPC PHARMA (01093) rose more than 3% in the last trading session. As of the time of writing, it rose by 2.92% to HK$7.75, with a turnover of HK$515 million. On the news front, on December 8th, CSPC PHARMA announced that its subsidiary, CSPC PHARMA Baike (Shandong) Biopharmaceutical Co., Ltd., has had the second application for marketing approval of Semaglutide Injection accepted by the National Medical Products Administration of the People's Republic of China (NMPA). This application is for the indication of long-term weight management in overweight/obese adult patients on the basis of controlling diet and increasing physical activity. Previously, the indication for the approval of Semaglutide for blood sugar control in adult type 2 diabetes patients was accepted by the NMPA in August 2025. According to the announcement, this application is based on a Phase III clinical trial. The results of this clinical trial show that in obese adults without diabetes, the product can significantly reduce weight and waist circumference, improve blood sugar, blood lipid, and liver enzyme levels. Compared to Novo Nordisk's Semaglutide, its effectiveness is highly consistent, its safety profile is similar, and it is well tolerated, with a slightly lower incidence of adverse events. Based on its advantages in efficacy, safety, and formulation, this product has significant clinical value.